Lomustine–temozolomide combination efficacious in newly diagnosed glioblastoma

The prognosis of patients with glioblastoma remains dismal, with median overall survival (OS) durations of ~15 months. New findings of a phase III trial indicate that adding lomustine to the standard treatment regimen improves the outcome of certain patients.

On the basis of evidence from a single-arm phase II study in 31 patients indicating an exclusive OS benefit, this phase III trial enrolled only patients with newly diagnosed MGMT promoter-methylated glioblastoma. In general, these patients have better responses to therapy and, thus, OS than those with MGMT promoter-unmethylated disease. After surgery, patients received standard daily radiotherapy either with daily temozolomide followed by six cycles of adjuvant temozolomide (n = 63), or with one course of lomustine and temozolomide chemotherapy (during the first week) followed by five additional cycles of lomustine and temozolomide (n = 66).

Median OS was 48.1 months with the lomustine–temozolomide regimen versus 31.4 months with temozolomide alone (HR 0.60, 95% CI 0.35–1.03; P = 0.0492). In both groups, the median progression-free survival was 16.7 months (P = 0.4113).

The frequency of grade 3–4 adverse events occurring up to 30 days after the end of study treatment was higher with lomustine–temozolomide than with temozolomide alone (59% versus 51%). No treatment-related deaths were reported. Notably, lower proportions of patients in the experimental arm received all six courses of chemotherapy (39% versus 60%) and the maximum temozolomide dose (38% versus 67%).

The investigators acknowledge that further studies in large cohorts are needed to confirm their findings. However, the current data indicate that the lomustine–temozolomide regimen has the potential to become a new standard of care.


Original article

  1. Herrlinger, U. et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial. Lancet 393, 678–688 (2019)

Download references

Author information

Correspondence to David Killock.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Killock, D. Lomustine–temozolomide combination efficacious in newly diagnosed glioblastoma. Nat Rev Clin Oncol 16, 273 (2019).

Download citation